Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus
Inadequate Glycaemic Control

Interventions: Drug: Dapagliflozin
Drug: Placebo for Dapagliflozin
Drug: Placebo for Saxagliptin
Drug: Saxagliptin

First Posted Date: 2016-02-12

Last Posted Date: 2018-10-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 905

Registration Number: NCT02681094

Locations: 🇷🇺
Research Site, Vladikavkaz, Russian Federation

To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: AZD5634 for infusion
Drug: AZD5634 for inhalation
Other: Placebo

First Posted Date: 2016-02-10

Last Posted Date: 2018-11-05

Lead Sponsor: AstraZeneca

Target Recruit Count: 63

Registration Number: NCT02679729

Locations: 🇺🇸
Research Site, Baltimore, Maryland, United States

Open, Randomised, Multi-center Study of on Demand Versus Continuous Esomeprazole Treatment in Patient With GERD

Phase 3

Completed

Conditions: Gastroesophageal Reflux

Interventions: Drug: Esomeprazole

First Posted Date: 2016-02-02

Last Posted Date: 2016-02-02

Lead Sponsor: AstraZeneca

Target Recruit Count: 877

Registration Number: NCT02670642

Locations: 🇩🇪
Gemeinschaftspraxis, Köln, Germany
🇩🇪
Frankenwaldklinik, Kronach, Germany
🇦🇹
Hanusch Hospital, Wien, Austria

and more 57 locations

A Study of Lanabecestat (LY3314814) in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lanabecestat

First Posted Date: 2016-01-26

Last Posted Date: 2019-11-01

Lead Sponsor: AstraZeneca

Target Recruit Count: 18

Registration Number: NCT02663128

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

Phase 1

Completed

Conditions: Carcinoma, Squamous Cell of Head and Neck
Stomach Neoplasms
Ovarian Neoplasms
Carcinoma, Pancreatic Ductal
Esophageal Squamous Cell Carcinoma
Triple Negative Breast Neoplasms
Fallopian Tube Neoplasms
Peritoneal Neoplasms
Esophagogastric Junction Neoplasms
Small Cell Lung Carcinoma

Interventions: Drug: oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid)
Drug: carboplatin + etoposide
Drug: paclitaxel + carboplatin
Drug: nab-paclitaxel (paclitaxel-albumin) + carboplatin
Drug: gemcitabine + carboplatin
Biological: durvalumab
Drug: nab-paclitaxel (paclitaxel-albumin) + gemcitabine
Biological: tremelimumab
Drug: cisplatin + 5-fluorouracil (5FU)

First Posted Date: 2016-01-18

Last Posted Date: 2020-08-20

Lead Sponsor: AstraZeneca

Target Recruit Count: 32

Registration Number: NCT02658214

Locations: 🇰🇷
Research Site, Seoul, Korea, Republic of

A Phase I Study to Assess PK of AZD7986 Alone & With Verapamil, Itraconazole or Diltiazem in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: AZD7986
Drug: Verapamil
Drug: Itraconazole
Drug: Diltiazem

First Posted Date: 2016-01-12

Last Posted Date: 2018-02-23

Lead Sponsor: AstraZeneca

Target Recruit Count: 15

Registration Number: NCT02653872

Locations: 🇬🇧
Research Site, London, United Kingdom

A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects

Phase 1

Completed

Conditions: Asthma
Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: AZD7594 Solution for infusion (150 μg intravenous formulation)
Drug: AZD7594 Oral suspension (1200 μg oral formulation)
Drug: AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler)
Drug: AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler)
Drug: AZD7594 Pressurized inhalation suspension (400 μg) by pMDI

First Posted Date: 2016-01-07

Last Posted Date: 2017-06-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 30

Registration Number: NCT02648438

Locations: 🇺🇸
Research Site, Baltimore, Maryland, United States

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men

Phase 1

Completed

Conditions: Chronic Obstructive Pulmonary Disease COPD
Asthma

Interventions: Drug: AZD7594 inhalation powder (200 μg)
Drug: AZD7594 inhalation powder (400 μg)
Drug: AZD7594 pressurized inhalation suspension (200 μg)
Drug: AZD7594 placebo inhalation powder
Drug: AZD7594 placebo pressurized inhalation suspension

First Posted Date: 2016-01-01

Last Posted Date: 2018-02-19

Lead Sponsor: AstraZeneca

Target Recruit Count: 27

Registration Number: NCT02645253

Locations: 🇺🇸
Research Site, Glendale, California, United States

Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase

Phase 1

Completed

Conditions: Solid Malignancies

Interventions: Drug: [14C]AZD2014
Drug: Multiple dose AZD2014
Drug: Fulvestrant
Drug: Paclitaxel

First Posted Date: 2015-12-29

Last Posted Date: 2019-04-22

Lead Sponsor: AstraZeneca

Target Recruit Count: 4

Registration Number: NCT02640755

Locations: 🇬🇧
Research Site, Manchester, United Kingdom

Asthma Control, Quality of Life and Emotional Feelings in a Real Life Setting

Completed

Conditions: Asthma

First Posted Date: 2015-12-29

Last Posted Date: 2017-10-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 1232

Registration Number: NCT02640742

Locations: 🇯🇵
Fukuokaken Saiseikai Futsukaichi Hospital, Chikushino, Fukuoka, Japan
🇯🇵
Japan Community Health Care Organization Kurume General Hospital, Kurume, Fukuoka, Japan
🇯🇵
Omuta Tenryo Hospital, Omuta, Fukuoka, Japan

and more 54 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy